Pharvaris

Pharvaris

Yahoo Finance • 20 days ago

Claude AI’s Newest Stock Picks Are Also Hedge Fund Favorites: One Breakout Biotech, One AI Chip Bet

Note: the trade details cited in this article come from The Claude Portfolio account on X, a third-party account not affiliated with Anthropic. It tracks how different AI models would trade if given a live portfolio. Claude AI recently add... Full story

Yahoo Finance • last month

After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over?

Key Points Schikan sold 37,600 shares over June 29, 2026 and June 30, 2026, generating ~ $1.33 million in gross proceeds based on a weighted average price of around $35.41 per share. This transaction represented 10.66% of his direct holdi... Full story

Yahoo Finance • last month

Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema

Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedemaExplains the scientific foundation for targeting the bradykinin B2 receptor as a thera... Full story

Yahoo Finance • 3 months ago

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors

Key Points Saturn V sold 1,504,880 shares of Ocular Therapeutix in the first quarter; the estimated transaction value was $14.34 million. Meanwhile, the quarter-end position value declined by $18.27 million, reflecting both share sales an... Full story

Yahoo Finance • 4 months ago

Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference

ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-m... Full story

Yahoo Finance • 5 months ago

Texas Instruments upgraded, Circle downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Stifel upgraded Texas Instruments (TXN... Full story

Yahoo Finance • 5 months ago

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit

Key Points 5AM Venture Management sold 365,053 shares of Dianthus Therapeutics in the fourth quarter. The quarter-end position value decreased by $14.36 million as a result of the sale, which marked a full exit from Dianthus. The position... Full story

Yahoo Finance • 6 months ago

Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology

Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of RAPIDe-3 endpoints ZUG, Switzerland, Marc... Full story

Yahoo Finance • 8 months ago

What Does Wall Street Think About Pharvaris N.V. (PHVS)?

Pharvaris N.V. (NASDAQ:PHVS) is one of the best small cap stocks to buy with huge upside potential. Morgan Stanley analyst Maxwell Skor reiterated a Buy rating on Pharvaris N.V. (NASDAQ:PHVS) on December 15, setting a $41 price target. Pha... Full story

Yahoo Finance • 9 months ago

This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy?

Key Points Austin-based Saturn V Capital Management acquired 886,332 shares of Pharvaris in the third quarter. Saturn V now holds 886,332 PHVS shares valued at $22.1 million. PHVS is a new addition, accounting for 4.9% of 13F AUM, which p... Full story

Yahoo Finance • 9 months ago

Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks

Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p<0.0001)All secondary efficacy endpoints met (p<0.0001), including End of Progression™1 (median 17.47 minutes) and c... Full story

Yahoo Finance • 9 months ago

Biotech Stock Gets Booted in Latest Fund Update

Key Points Sold 1,447,267 shares, a net position change of $110.43 million Post-trade stake: 0 shares, $0 value The position was previously 13.8% of the fund's AUM as of the prior quarter, marking a significant portfolio shift These 10 st... Full story

Yahoo Finance • 9 months ago

Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update

Topline data for RAPIDe-3, a pivotal Phase 3 study of deucrictibant immediate-release capsule for the on-demand treatment of HAE attacks, expected in 4Q2025Enrollment in CHAPTER-3, a pivotal Phase 3 study of deucrictibant extended-release... Full story

Yahoo Finance • 10 months ago

Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting

Open-label prophylaxis data supporting the long-term safety profile and sustained benefits of deucrictibant, as well as clinical validation data of a kinin biomarker assay were highlighted in two oral presentationsFinal data from participa... Full story

Yahoo Finance • last year

Pharvaris stock price target lowered to $52 by Citizens JMP

Investing.com - Citizens JMP lowered its price target on Pharvaris B.V. (NASDAQ:PHVS) to $52.00 from $55.00 on Wednesday, while maintaining a Market Outperform rating on the stock. Currently trading at $21.09, the company shows a strong fi... Full story

Yahoo Finance • last year

Pharvaris NV (NASDAQ:PHVS) Reports Wider Q2 2025 Loss, Highlights Clinical Trial Progress

PHARVARIS NV (NASDAQ:PHVS [https://www.chartmill.com/stock/quote/PHVS]) REPORTS Q2 2025 EARNINGS: WIDER LOSS THAN EXPECTED, CLINICAL PROGRESS IN FOCUS Pharvaris NV (NASDAQ:PHVS [https://www.chartmill.com/stock/quote/PHVS]) reported a seco... Full story

Yahoo Finance • last year

Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

ZUG, Switzerland, July 24, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with... Full story

Yahoo Finance • last year

Pharvaris prices $175M securities offering

Pharvaris (NASDAQ:PHVS [https://seekingalpha.com/symbol/PHVS]) priced [https://seekingalpha.com/pr/20174484-pharvaris-announces-pricing-of-upsized-175-million-public-offering-of-ordinary-shares-and-pre]an underwritten offering of 8.25 mill... Full story

Yahoo Finance • last year

Pharvaris stock awaits pivotal HAE therapy data as BofA reiterates Underperform

Investing.com - BofA Securities has reiterated its Underperform rating and $14.00 price target on Pharvaris B.V. (NASDAQ:PHVS), currently trading at $18.68, as the company announced updated timelines for its hereditary angioedema (HAE) the... Full story

Yahoo Finance • last year

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

ZUG, Switzerland, July 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediate... Full story